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Abstract
Objective: To determine the value of international prostate symptom scoring (IPSS) system in management of patients 
with benign prostatic hyperplasia (BPH) in Jos, Nigeria.
Materials and Methods: This was a prospective study of 104 newly diagnosed patients with BPH from June 2006 
to July 2007. Patients’ symptoms were initially evaluated by administering a pretreatment IPSS/Quality of Life Score 
(QOLS). This categorized patients into mild, moderate, and severe symptom groups. The mild symptom group had 
watchful waiting as mode of management. The moderate symptom group received doxazosin, an alpha blocker, while 
the severe symptom group had prostatectomy. A post-treatment IPSS/QOLS was administered 3 months after. Mean 
changes in IPSS/QOLS was calculated and subjected to paired student’s t- test for significance in changes. Spearman’s 
correlation coefficient was used to test significance between correlations.
Results: Mean age of patients was 64.3 years. 3 patients (2.9%), 53 patients (51.0%), and 48 patients (46.1%) fell into 
the minor, moderate, and severe symptom categories, respectively. The QOLS correlated with IPSS. There was a mean 
change in symptom scores of +2.3 for the minor symptom category, -8.1 (P < 0.001) for IPSS and -1.7 (P < 0.001) for 
QOLS in the moderate symptom category, and -24.6 (P < 0.001) for IPSS and -4.0 (P < 0.05) for QOLS in the severe 
symptom category.
Conclusion: The study has shown that IPSS is a valuable tool in management of patients with BPH.
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Introduction
Benign prostatic hyperplasia (BPH) is the most common 
cause of bladder outlet obstruction in men older than 
50 years of age.[1,2] Clinically apparent BPH represents 
a considerable health problem for older men due to the 
negative effects it has on quality of life.[3]
In any disease, measuring physiological status alone gives 
an incomplete picture of health, defined by the WHO as a 
state of complete physical, mental, and social well being, and 
not merely the absence of disease or infirmity. Assessment 
of this broad definition in individual patients necessitates 
understanding the patients’ perceptions of disease, which 
are based on symptoms and the bother they cause.[4] Most 
patients seeking treatment for BPH do so because of 
bothersome symptoms that affect the quality of their lives. 
To the patient, of course, relief of symptoms is the single 
most important outcome, not flow rate, detrusor pressure, 
or urethral resistance factors.[5] The availability of reliable 
symptom scores is important to determine the severity of 
the disease, to assess the patient’s symptoms, to determine 
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points of necessary intervention, and to document the 
response to therapy. Such assessment tools also allow 
comparison of the effectiveness of various interventions and 
facilitate the monitoring of disease progression in individual 
patients.[4] Symptom indices also enhance communication 
between patient and doctor.[6] Combining information from 
symptom indices with other measurements of disease such as 
physiological investigations allows a more global assessment 
of health to be made.[4]
The validated scoring systems include the American 
Urological Association Index, later adopted by WHO as the 
International Prostate Symptom Score, the Maine Medical 
Assessment Program Score, and the Danish Prostatic 
Symptom Score.[4]
The most widely used score internationally is the IPSS, based 
on the AUA symptom score.[7] The IPSS is a well‑designed 
and extensively studied scale for quantifying lower urinary 
tract symptoms (LUTS) suggestive of benign prostatic 
obstruction[8] and has been validated in several studies.
International Prostate Symptom Scoring system has not 
found wide application in our hospitals including Jos 
University Teaching Hospital (JUTH). In other places, it 
has already become a valuable tool in the management of 
BPH. This study aims to establish a case for routine use of 
this scoring system.
Materials and Methods
The study spanned a period of 14 months from June 2006 to 
July 2007 in JUTH and ECWA Evangel Hospital. This is a 
hospital‑based study and the population studied was drawn 
from newly diagnosed cases of BPH in the two hospitals. 
Approval for the study was obtained from the research and 
ethical committees of JUTH and ECWA Evangel hospital. 
Informed consent from patients who fulfilled the inclusion 
criteria was also obtained. Diagnosis of BPH was based on 
suggestive history, digital rectal examination, abdomino‑
pelvic ultrasound, cystoscopy to exclude bladder pathology, 
quantitative PSA, and prostatic biopsies for  Prostate specific 
antigen (PSA) above normal level to exclude carcinoma of 
the prostate (Normal PSA value is 0–4 ng/ml).
A pretreatment IPSS was administered to the patient. 
The literate patients filled out their questionnaires, while 
the researcher translated and filled the questionnaires for 
the illiterate patients. The pretreatment IPSS was used 
to categorize patients into mild (IPSS 0–7), moderate 
(IPSS 8–19), or severe (IPSS 20–35) groups. The Quality 
of Life Score (QOLS) was also recorded. Based on these 
categories, treatment was assigned. The minor symptom 
group underwent watchful waiting. The moderate symptom 
group had medical therapy with a1‑blocker; doxazosin at 
the dose of 4 mg per day. This therapy lasted for 3 months. 
The severe symptom category had open prostatectomy 
(transvesical). The choice of transvesical prostatectomy 
was based on the fact that it was the preferred method 
of the surgeons; moreover, the facilities for transurethral 
resection of the prostate were not available in both centers 
at the time of the study. Watchful waiting in these patients 
entailed 2 weekly reassessment for worsening symptoms or 
development of complications like acute urinary retention, 
hematuria, bladder stones, renal impairment, and recurrent 
urinary tract infections.
Selected patients were subsequently supervised over a 
period of 3 months in the surgical outpatients intermittently 
to confirm that instructions were being followed and a 
post‑treatment IPSS with the QOLS taken at 3 months to 
ascertain changes in IPSS and QOLS due to intervention. 
Each patient was interviewed using a standard proforma 
(Appendix) to obtain demographic and social history.
The percent drop in score was calculated ([Score [pre] ‑ 
Score [post]] × 100/Score [pre] = percent improvement 
in score). This was regarded as a predictive value.
Results collected from the data were analyzed using a 
multipurpose computer statistical programme EPI‑INFO and 
Microsoft Excel 8.0 with the assistance of a computer analyst. 
Results were expressed using tables as means, standard 
deviation (SD), and ranges. Charts and pictograms were 
used where necessary. Spearman’s correlation coefficient was 
used to test significance in correlation between qualitative 
variables. Paired student t‑test was used to compare means 
of variables measured to test for significance. P values ≤ 0.05 
were considered significant association.
Results
The number of patients initially recruited for the study 
was 124. However, a total of 20 patients were lost to 
follow‑up either before or after intervention following the 
pretreatment IPSS. These patients were excluded from the 
analysis. A total of 104 patients completed the study and 
were analyzed.
The mean age of the patients was 64.3 years (SD = 8.6, 
range = 45–91). Majority, 42 (40%), of the patients were 
aged 60 to 69 years. In terms of literacy level, 52 (50.0%) 
had no formal education, 14 (13.5%) each had primary 
and secondary education, while 24 (23.0%) had tertiary 
education.
The International Prostate Symptom Score (IPSS) and 
Quality of Life Assessment score (QOLS) distribution is 
as follows: Out of the 104 patients, 3 patients (2.9%), 53 
patients (51.0%), and 48 patients (46.1%) fell into the 
minor, moderate, and severe categories, respectively, as 
shown in Figure 1.
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In the minor category, mean of the pretreatment score for 
IPSS was 5.7 (SD = 0.6, range = 5–6) and 2.3 (SD = 0.6) 
for QOLS.
For the moderate category, mean of the pretreatment 
score for IPSS was 15.5 (SD = 3.1, range = 8–19) and 4.1 
(SD = 0.9) for QOLS.
For the severe category, mean of the pretreatment score 
for IPSS was 28.2 (SD = 4.3, range = 20–35) and 5.0 
(SD = 0.9) for QOLS.
Spearman’s correlation coefficient was 0.72 (P < 0.001).
The mean ± SD post‑treatment IPSS and QOLS, 
respectively, at 3 months were as follows:
For the minor category: IPSS was 8.0 ± 1 and QOLS was 
2.3 ± 0.6.
Mean magnitude of change in IPSS between the post 
treatment and pretreatment was +2.3 ± 1.5 (41%). No 
change noted in QOLS
For the moderate category: IPSS was 7.4 ± 4.9 and QOLS 
was 2.4 ± 1.0.
Mean magnitude of change in IPSS between the post 
treatment and pretreatment was ‑8.1 ± 5.4 (52%). The 
change in QOLS was ‑1.7 (41%).
For the severe category: IPSS was 3.6 ± 1.5 and QOLS 
was 1.1 ± 0.60.
Mean magnitude of change in IPSS between the post 
treatment and pretreatment was ‑24.6 ± 4.4 (87%). The 
change in QOLS was ‑4.0 (79%).
These changes are illustrated in Table 1 and Figure 2 (a and b).
The correlation between quality of life and post treatment 
IPSS was 0.78 (P < 0.001).
The changes noted in the pre‑ and post treatment IPSS and 
Table 1: Summary of changes in IPSS and QOLS
Category Pretreatment 
IPSS score (mean)










Mild 5.7 8.0 +2.3 (41%) 2.3 2.3 0
Moderate 15.5 7.4 -8.1 (52%) 4.1 2.4 −1.7 (41%)
Severe 28.2 3.6 −24.6 (87%) 5.0 1.1 -4.0 (79%)
Figure 2: (a) Column chart of changes in IPSS at 3 months post treatment. (b) Column chart of changes in IPSS at 
3 months post treatment
ba
Figure 1: Pie chart showing pretreatment severity of symptoms 
based on IPPS
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also in the QOLS were subjected to a test of significance 
using the t test: paired two samples for means.
The patients were not enough in the minor category to 
merit statistical analysis, zero change was noted in QOLS 
in the minor category.
For the moderate category, P < 0.001 for both IPSS and 
QOLS.
For the severe category, P < 0.001 for both IPSS and QOLS.
The predictive value was found to be 87% for the severe 
group treated by surgery and 52% for the moderate group 
treated by the alpha adrenergic blocker, doxazosin.
Discussion
Increasing costs and morbidity related to frequency of 
prostatectomies have led to a search for tools for better 
evaluation, predictors of good outcome, as well as to 
alternative treatment strategies. Symptoms lead the patient 
to seek treatment and symptom improvement is the chief 
goal for the patient.
Studies using symptom indices to measure symptoms, to assess 
severity of symptoms and the bother caused by them, and to 
follow changes with time and perhaps treatment have been 
undertaken in men with diagnosed symptomatic BPH.[4,9‑11].
Patient’s age distribution in this study is consistent 
with previous studies by others, which have shown that 
the prevalence of LUTS suggestive of benign prostatic 
obstruction increases with age.[7,8,12]
In the initial assessment of patients, it was possible using IPSS 
to categorize patients according to severity of symptoms into 
minor, moderate, and severe groups and to also determine the 
level of bothersomeness of their symptoms. It is noteworthy 
that most of the patients (51.0%) fell into the moderate 
category and that the mean QOLS increased with increasing 
mean IPSS. Spearman’s coefficient of 0.72 showed significant 
correlation between QOLS and pretreatment IPSS. The 
relative distribution of scores in this study is similar to the 
result seen in the study by McConnell et al.[13]
The role of IPSS in the choice of treatment modality 
and monitoring response to therapy has been well 
documented. Prior to the 1980s, prostatectomy was the 
only widely accepted intervention for BPH. However, in 
men with symptomatic BPH, it is clear that progression is 
not inevitable and that some men undergo spontaneous 
improvement or resolution of their symptoms.[14] Previously, 
all these patients would have had prostatectomy whether it 
was actually indicated or not. This initial assessment result 
puts the urologist in a better position to understand the 
magnitude of the patient’s problem and expectation and to 
choose the appropriate intervention for the patient.
These patients were subjected to different management 
protocols based on their scores. The overall change in 
the pretreatment IPSS and QOLSs for the 104 patients 
was found to be statistically significant (P < 0.001) after 
3 months of intervention.
There was worsening of patient’s symptoms, as depicted 
by increased IPSS and QOL scores in the minor symptom 
category who were managed by watchful waiting for 3 months. 
However, the number of patients in this group was too small 
to merit statistical analysis. Other studies have shown varying 
results with this category of patients. McConnell et al.[13] in 
their detailed review of interventions for BPH noted some 
improvements in symptoms in about 40% of patients studied, 
but more than one‑third of patients actually experienced 
deterioration under the watchful waiting strategy. Wasson 
et al.[15] also reported disease progression in 47% of patients 
randomized to watchful waiting. They attributed this to 
increasing postvoidal residual urine (PVR) or symptom 
score. Conversion to other treatment protocol usually 
becomes necessary in such group of patients. However, it is 
known that some group of patients experience no change 
in their symptom scores for several months.[13] Based on the 
findings in this study, alternative treatment protocols like 
alpha adrenergic blockers should be instituted for worsening 
symptoms in the mild group or even surgery if complications 
set in. However, in our society patients usually present when 
their symptoms become a source of worry for them. Watchful 
waiting may not be a viable management option.
There was symptom improvement in the moderate symptom 
category treated with alpha adrenergic blocker. Doxazosin 
was used in this study. The mean magnitude of change in 
IPSS and QOLS, 8.1 (52%) and 1.7 (41%), was statistically 
significant (P < 0.001) and is comparable to findings in other 
studies. Nwofor et al.[16] employed doxazosin in their study 
and noted comparable changes in IPSS scores. MacDonald 
and co‑workers[17] in one of the largest series on efficacy of 
alpha blockers; a meta‑analysis to evaluate the efficacy and 
adverse effects of doxazosin for treating LUTS compatible 
with benign prostatic obstruction noted a mean magnitude 
of change in IPSS of 9.2 over a 14‑week study period and 7.2 
for alfuzosin over the same period. They also noted that the 
effects of the different alpha adrenergic blockers on patients 
with moderate IPSS were comparable with slight differences.
In the severe symptom category, open prostatectomy 
was offered because of surgeons preference. Moreover, 
facilities for transurethral resection of the prostate were 
not available in both centers at the time of the study. The 
mean magnitude of change was 24.6 (87%) for the symptom 
score and 4.0 (79%) for the quality of life. This represents 
a tremendous improvement in patient’s symptoms. The 
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findings were statistically significant (P < 0.001). This study 
has demonstrated that the magnitude of improvement is 
greater for surgical treatment modalities than for nonsurgical 
treatment options.
For IPSS change after prostatectomy, others reported mean 
IPSS improvements of 10.5 to 16 points.[7,18‑21] Possible 
reasons for these differences may be late presentation to 
health care until symptoms are very severe due to the high 
level of illiteracy in our environment. Most of the patients 
in this study had no formal education. Differences in study 
design may be another reason.
Surgical options have the highest degree of symptom 
improvement.[13] Efficacy, in terms of durable improvement 
in symptom score, is superior to other treatment options 
available for the obstructing prostate gland,[13] as was the 
finding in this study. There may be need for further studies 
to define long‑term outcome.
There was neither significant morbidity nor mortality 
recorded in this study
Role of IPSS in Outcome Prediction
The probability of symptom improvement measured by the 
IPSS is highest for surgical modality with a predictive value 
of 87%. However, this does not mean that every patient with 
symptoms of lower urinary obstruction due to BPH should 
have surgery, since medical therapy with alpha adrenergic 
blockers has also been shown to be effective in well‑selected 
patients obviating the risks associated with surgical procedures.
Conclusions and Recommendations
Conclusion
This study has shown that the IPSS is a valuable tool in 
the management of patients with BPH in terms of initial 
assessment and categorization of patients. It is useful in 
detecting, measuring, and monitoring change in symptoms 
following treatment. It could be used to guide choice of 
treatment modality. It is also a valuable tool for evaluation 
of treatment outcome and follow‑up; and its application 
in measuring response to therapy and predicting outcome 
cannot be overemphasized.
The use of this scoring system would definitely improve the 
management of patients with BPH and would provide a basis 
for comparison with other treatment modalities in the future.
It is therefore recommended as follows:
1.  IPSS should be used routinely in management of 
patients with BPH.
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v. Occupation: i. C/S ii. Farmer iii. Military 
iv  Businessman
v. others ( specify)…………………....…………….
vi. Marital status
vii. Literacy level:
 Primary  ( )
 Secondary (  )
 Tertiary  (  )
 Non‑formal (  )
 None  (  )
B. DIAGNOSIS OF BPH:
i. Clinically (History & DRE)
ii. Ultrasound
iii Cystoscopy
C. PRETREATMENT IPSS SCORE
D. TYPE OF TREATMENT GIVEN:
i. Watchful waiting
ii. Medical; Doxazosin ( cardura)
iii Surgical
 a. Trransvesical prostatectomy
 b. Others
E. POST TREATMENT IPSS SCORE AT 3 
MONTHS……………
References
1.  Weinerth JL, Robertson CN. The male genital system. In: Sabiston DC, 
Lyerly KH, editors. Textbook of surgery: The biological basis of modern surgical 
practice. 15th ed. Philadelphia: W B Saunders; 1997. p. 1457‑78.
2.  Barry, MJ, Adolfsson, J, Batista, JE Measuring the symptoms and health impact 
of benign prostatic hyperplasia and its treatments. In: Denis, L, Griffiths, K, 
Khoury, S eds. (1998) Proceedings of the 4th International Consultation of 
Benign Prostatic Hyperplasia (BPH). SCI, Paris, pp. 265‑321
3.  Donovan JL, Kay HE, Peters TJ, Brookes ST, Neal DE, Abrams P, et al. Using the 
ICSQol to measure the impact of lower urinary tract symptoms on quality of 
life: Evidence from the ICS‑BPH study. International continence society BPH. 
Br J Urol 1997;80:712‑21.
4.  Hines JEW. Symptom indices in bladder outlet obstruction. Br J Urol 
1996;77:494‑501.
278 Nigerian Journal of Clinical Practice • Jul-Sep 2013 • Vol 16 • Issue 3
Amu, et al.: Value of IPSS in BPH in Jos, Nigeria
5.  Mebust WK, Roizo R, Schroeder F, Villers A. Correlations between pathology, 
clinical symptoms and the course of the disease. The International Consultation 
on Benign Prostatic Hyperplasia ‑ Proceedings. Paris, 1991; 53:51‑62.
6.  O’Leary MP, Barry MJ, Fowler FJ. Hard measures of subjective outcomes: 
Validating symptom indexes in urology. J Urol 1992;148:1546‑8.
7.  Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, 
et al. The American Urological Association symptom index for benign prostatic 
hyperplasia. J Urol 1992;148:1549‑57.
8.  Hakenberg OW, Pinnock CB, Marshall VR. Preoperative urodynamic and 
symptom evaluation of patients undergoing transurethral prostatectomy: 
Analysis of variables relevant for outcome. BJU Int 2003;91:375‑9.
9.  Kirby RS. The clinical assessment of benign prostatic hyperplasia. Cancer 
1992;70:284‑90.
10.  Denis LJ. Future implications for the management of benign prostatic 
hyperplasia. Eur Urol 1994;25:29‑34.
11.  Cockett ATK, Barry MJ, Holtgrewe HL, Sihelnick S, Williams R, McConnell J. 
Indications for treatment for benign prostatic hyperplasia. The American 
Urological Association Study. Cancer 1992;70:280‑3.
12.  Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism 
as risk factors for prostatectomy. Prostate 1990;16:253‑7.
13.  McConnell JD, Barry MJ, Bruskewitz RC, Bueschen AJ, Denton SE, 
Holtgrewe HL, et al. Benign Prostatic Hyperplasia; Diagnosis and Treatment. 
Clinical Practice Guideline No. 8. AHCPR Publication No. 94‑0582. Rockville, 
MD: Agency for Health Care Policy and Research, Public Health Service. US: 
Department of Health and Human Services; 1994.
14.  Joseph C. Presti MD Jr. Neoplasms of the Prostate Gland. In: Tanagho EA, 
McAninch JW, eds. Smith's General Urology 15th ed. New York, NY: Lange 
Medical Books/McGraw ‑Hill/Appleton and Lange; 2004. p. 12‑20.
15.  Wasson JH, Reda DJ, Bruskewitz RC. A comparison of transurethral surgery 
with watchful waiting for moderate symptoms of benign prostatic hyperplasia. 
N Engl J Med 1995;332:75‑9.
16.  Nwofor AME, Dogunro AS. Doxazosin in the treatment of elderly Nigerians 
with BPH. Afr J Urol 2002;8:56‑61.
17.  MacDonald R, Wilt TJ, Howe WR. Doxazosin for treating lower urinary tract 
symptoms compatible with benign prostatic obstruction: A systematic review 
of efficacy and adverse effects. BJU Int 2004;94:1263‑70.
18.  Emberton M, Black N, Blandy JP, McPherson K, Devlin BH, Neal DE, et al. The 
effectiveness of prostatectomy in reducing symptoms and improving the quality 
of life in 5131 men. J Urol 1995;153:317‑20.
19.  Keoghane S, Cranston D, Lawrence K, Dol lH, Fellows G, Smith J. The Oxford 
laser prostate trial: A prospective randomised controlled trial of contact 
vaporisation of the prostate versus TURP. J Urol 1995;153:230‑4.
20.  Gill HS, Kabalin JN. Urodynamic evaluation of patients in a randomised study 
of TURP versus laser prostatectomy: Preoperative and one‑year follow up. 
Neurourol Urodyn 1993;12:372‑5.
21.  Horninger W, Janetschek G, Pointer J, Watson G, Bartsch G. Are TULIP, 
interstitial laser and contact laser superior to TURP? J Urol 1995;153:413‑7.
How to cite this article: Amu OC, Udeh EI, Ugochukwu AI, Dakum NK, 
Ramyil VM. The value of international prostate symptom scoring system in 
the management of BPH in Jos, Nigeria. Niger J Clin Pract 2013;16:273-8.
Source of Support: Nil, Conflict of Interest: None declared.
